

41443



1635
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael EISENHUT et al

Serial No.: 09/781,980

Filed: 14 February 2001

For: OLIGONUCLEOTIDE CONJUGATES

Group Art Unit: 1635

Examiner: J. Schultz

#9/K.T.
2/26
A

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB 19 2003
TECH CENTER 1600/2900

Sir:

This Amendment is in response to the Office Action mailed 13 August 2002.
Attached hereto and herein incorporated by reference is a Petition for Extension of Time for a
three-month extension making the due date for response 13 February 2003.

Kindly amend the application as follows.

IN THE SPECIFICATION:

Kindly substitute the last paragraph on page 10 with the following:

A'
The inhibition of bcl-2 is preferred, since a large number of tumor types show an
aberrant expression of the proto-oncogene bcl-2, which results in an increase of the
concentration of the protein bcl-2. As is known, this protein inhibits apoptosis. Thus, the
inhibition of the expression of the bcl-2 gene so as to effect apoptosis of the tumor cells and
thus the elimination of the tumor, is a significant approach for a cancer therapy. Therefore,